

Human Recombinant G-Protein Coupled Receptor 103 Stable Cell Line

Technical Manual No. TM0511

Version 10132010

I	Introduction	1
II	Background.....	1
III	Representative Data.....	2
IV	Thawing and Subculturing.....	2
V	References	3
	Limited Use License Agreement.....	4

I. Introduction

Catalog Number: M00321

Cell Line Name: CHO-K1/GPR103/ Gα15

Gene Synonyms: AQ27; GPR103; MGC149217; SP9155

Expressed Gene: Genbank Accession Number NM_198179; no expressed tags

Host Cell: CHO-K1/Gα15

Quantity: Two vials of frozen cells (3×10⁶ per vial)

Stability: 16 passages

Application: Functional assay for GPR103 receptor

Freeze Medium: 45% culture medium, 45% FBS, 10% DMSO

Complete Growth Medium: Ham's F12, 10% FBS

Culture Medium: Ham's F12, 10% FBS, 100 µg/ml Hygromycin B, 400 µg/ml G418

Mycoplasma Status: Negative

Storage: Liquid nitrogen immediately upon delivery.

II. Background

GPR103 is known as an orphan G protein-coupled receptor with reported expression in brain, heart, kidney, adrenal gland, retina, and testis. GPR103 mRNA has been reported to be highly expressed in the superficial layers of the entire spinal cord and a high density of 26RfA binding sites was observed in the superficial layers of the dorsal horn. QRFP binds and activates the human GPR103, as well as mouse GPR103A and GPR103B, with nanomolar affinities in transfected cells. Therefore, the current experiments investigated the effects of QRFP administration in rats and the effects of a high fat diet on prepro-QRFP mRNA and GPR103 receptor mRNA levels. 26RfA and QRFP are endogenous ligands of GPR103. An immunohistochemical study revealed that GPR103-like immunoreactivity (LI) was observed in the superficial layers of spinal dorsal horn, that QRFP-LI was observed in the dorsal root ganglion and that intrathecal 26RfA suppressed the expression of Fos-LI induced by paw formalin injection in the superficial layers of the spinal dorsal horn.

§: GenScript employs a PCR-based method to test the mycoplasma. The test covers 11 of the most common strains of mycoplasma, (covering approximately 95% of *M. fermentans*, *M. hyorhinis*, *M. arginini*, *M. orale*, *M. salivarium*, *M. hominis*, *M. pulmonis*, *M. arthritis*, *M. neurolyticum*, *M. hyopneumoniae* and *M. capricolum*) and one species *Ureaplasma* (*U. urealyticum*), with sufficient sensitivity and specificity.

III. Representative Data

Concentration-dependent stimulation of intracellular calcium mobilization by Human 26RFa in CHO-K1/GPR103/Gα15 and CHO-K1/Gα15 cells




Figure 1. Human 26RFa-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/GPR103/Gα15 and CHO-K1/Gα15 cells. The cells were loaded with Calcium-4 prior to stimulation with a GPR103 receptor agonist, Human 26RFa. The intracellular calcium change was measured by FlexStation. The relative fluorescent units (RFU) were plotted against the log of the cumulative doses (5-fold dilution) of Human 26RFa (Mean ± SD, n = 2). The EC₅₀ of Human 26RFa on GPR103 co-expressing with Gα15 in CHO-K1 cells was 2.0 nM. The S/B of Human 26RFa on GPR103 co-expressing with Gα15 in CHO-K1 cells was 23.

Notes:

- EC₅₀ value is calculated with four parameter logistic equation:

$$Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{-(\text{LogEC}_{50} - X) \cdot \text{HillSlope}})$$

X is the logarithm of concentration. Y is the response
 Y is RFU and starts at Bottom and goes to Top with a sigmoid shape.
- Signal to background Ratio (S/B) = Top/Bottom

IV. Thawing and Subculturing

Thawing: Protocol

- Remove the vial from liquid nitrogen tank and thaw the cells quickly in a 37°C water-bath.
- Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
- Pellet cells by centrifugation at 200 x g for 5 min, and discard the medium.
- Resuspend the cells in complete growth medium.
- Add 10 ml of the cell suspension in a 10 cm dish.
- Add Hygromycin B and G418 to concentrations of 100 µg/ml and 400 µg/ml respectively the following day.

Subculturing: Protocol

1. Remove and discard culture medium.
2. Wash cells with PBS (pH=7.4) to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 ml of 0.05% (w/v) Trypsin- EDTA (GIBCO, Cat No. 25300) solution to a 10 cm dish and observe the cells under an inverted microscope until cell layer is dispersed (usually within 3 to 5 minutes).
Note: To avoid clumping, do not agitate the cells by hitting or shaking the dish while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting, centrifuge the cells 200 x g for 5min, and discard the medium.
5. Resuspend the cells in culture medium and add appropriate aliquots of the cell suspension to new culture vessels.
6. Incubate cultures at 37°C.

Subcultivation Ratio: 1:3 to 1:8 weekly.

Medium Renewal: Every 2 to 3 days

V. References

1. Baribault H, Danao J, Gupte J, *et al.* (2006) The G-protein-coupled receptor GPR103 regulates bone formation. *Mol. Cell. Biol.* 26(2):709-17.
2. Takayasu S, Sakurai T, Iwasaki S, *et al.* (2006) A neuropeptide ligand of the G protein-coupled receptor GPR103 regulates feeding, behavioral arousal, and blood pressure in mice. *Proc Natl Acad Sci U S A.* 103(19):7438-43
3. Yamamoto T, Wada T, Miyazaki R. (2008) Analgesic effects of intrathecally administered 26RFa, an intrinsic agonist for GPR103, on formalin test and carrageenan test in rats. *Neuroscience.* 157(1):214-22
4. Primeaux SD, Blackmon C, Barnes MJ, *et al.* (2008) Central administration of the RFamide peptides, QRFP-26 and QRFP-43, increases high fat food intake in rats. *Peptides.* 29(11):1994-2000

GenScript USA Inc.
860 Centennial Ave., Piscataway, NJ 08854
Tel: 732-885-9188, 732-885-9688
Fax: 732-210-0262, 732-885-5878
Email: info@genscript.com
Web: <http://www.genscript.com>

Research Use Only

Limited Use License Agreement

This is a legal agreement between you (Licensee) and GenScript USA Inc. governing use of GenScript's stable cell line products and protocols provided to licensee. By purchasing and using the stable cell line, the buyer agrees to comply with the following terms and conditions of this label license and recognizes and agrees to such restrictions:

- 1) The products are not transferable and will be used at the site where they were purchased. Transfer to another site owned by buyer will be permitted only upon written request by buyer followed by subsequent written approval by GenScript.
- 2) The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party.
- 3) The products or its components are used for research purposes only.

GenScript USA Inc. will not assert against the buyer a claim of infringement of patents owned or controlled by GenScript USA Inc. and claiming this product based upon the manufacture, use or sale of a clinical diagnostic, therapeutic and vaccine, or prophylactic product developed in research by the buyer in which this product or its components has been employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on the use of this product for purposes other than research, contact Marketing Department, GenScript USA Inc., 860 Centennial Avenue, Piscataway, New Jersey 08854, U.S.A. Phone: 1-732-885-9188. Fax: 1-732-210-0262. Email: marketing@genscript.com.